Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma.
about
Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practiceSafety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancerA longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaComparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL StudyImpact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.Pharmacoeconomic effect of compliance with pharmacist's intervention based on cancer chemotherapy regimens: a cohort study.Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.Prediagnostic body weight and survival in high grade glioma.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practiceImpact of granulocyte colony-stimulating factors in metastatic colorectal cancer patients.Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin LymphomaToxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis.Improving adherence to oral cancer therapy in clinical practice.Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervous system lymphoma.Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.Comparison of two different formulas for body surface area in adults at extremes of height and weight.Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population.Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic.A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting.Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.Cancer in liver transplant recipients: management and outcomes.The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma.Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
P2860
Q34390036-55D726E0-2745-43E4-84A2-D2B3F29D458DQ34779671-FBC7057C-370A-41CA-9256-81C692A2E427Q35494151-8F0B875C-B85B-4D71-B70D-1D2954316B88Q35730160-41830355-E6E0-4400-BC0D-2862616B0406Q35894752-6B1B0497-7FF5-4797-A33C-C789381FC8EEQ36004954-CA6C86BA-B71E-44B6-A619-8C5BFCE6ADF0Q36243957-AE8260AC-7647-47C7-A672-B48415263EECQ36498360-CB544701-3973-4EAC-86A2-93703ACE69FEQ36507866-C2187487-82A4-4AFE-93B5-D178FBAAE657Q36769011-9EB45BC9-52C0-4E41-9C6C-E861946B06C4Q37060466-87042663-D735-4239-A1F4-8D0B1F0B770EQ37554901-820357A4-0E05-4F91-88A7-F81891BCB486Q37577685-0CFF8CDA-46EA-4B60-B4F9-EC629C3C9BA1Q37703409-EF94451E-00F1-490D-BEEC-3A55A2D496CDQ37710149-70BB2E1D-A780-4C58-9516-C9A4C37F330FQ38130610-ADDE7F4D-1980-4BEB-863B-FC13A5FE0D04Q38216035-0DF4C3EB-ED21-4298-BDDA-5CE62FB170A0Q38405004-ECB70DB4-999C-4BCC-BE3C-5E0B248A7254Q38711166-09B69E89-928F-49E9-A0FB-4EAD3221BFA9Q39074316-92518045-E3B2-48F6-835E-D20550A4717CQ39471971-A672AFE6-2FD7-45E1-B525-631BB236EE27Q39622633-EA874827-C3A8-4D35-BBFC-2585AC251AECQ39698919-3BA88B34-D20B-4B74-A122-F6C3232A740AQ40242261-52827605-37BD-418C-BB92-F3AFE7CCE602Q40245653-7C167517-CBE1-4926-AECA-74B48CC07CE7Q40523171-26FBEFC4-D2A0-4CE5-95A7-D113308B3860Q41139035-023754FC-F064-4BEB-9C11-C836E5E1FF1BQ44212969-E19FCE36-B022-4C51-A5FA-7AAF880BD6E1Q46080088-85880C2C-029C-482A-A34E-461C9D85EE23Q47733110-F20D0928-F33A-4195-92BF-2126374BB9A0Q47908189-9A880849-F4AF-43D8-B53A-3800D8867959Q47938059-6F76AE1D-5C9D-45D0-941D-9F40222B486FQ51017077-EFFB5AC0-B407-4E14-93F0-2C6C7DA2E55EQ51339494-C2FAC41C-6095-4599-8D41-687CCB49C3CAQ54187954-834ADCE9-C874-4CD7-9333-15BB846DE64BQ54339322-BE5AC234-4775-4B05-BFAF-7069426AA68DQ55664284-29B40090-2884-40AD-B3C7-517ED90E4FCFQ58767839-2D541290-6209-434F-A05F-B08376BCE86E
P2860
Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Relative dose intensity of che ...... cancer or aggressive lymphoma.
@en
Relative dose intensity of che ...... cancer or aggressive lymphoma.
@nl
type
label
Relative dose intensity of che ...... cancer or aggressive lymphoma.
@en
Relative dose intensity of che ...... cancer or aggressive lymphoma.
@nl
prefLabel
Relative dose intensity of che ...... cancer or aggressive lymphoma.
@en
Relative dose intensity of che ...... cancer or aggressive lymphoma.
@nl
P1476
Relative dose intensity of che ...... cancer or aggressive lymphoma.
@en
P2093
Hans Wildiers
Marcel Reiser
P304
P356
10.1016/J.CRITREVONC.2010.02.002
P577
2010-03-15T00:00:00Z